Attached files
| file | filename |
|---|---|
| 8-K - CURRENT REPORT - BIOLOGIX HAIR INC. | f8k012413_biologix.htm |
| EX-99.1 - NEWS RELEASE DATED JANUARY 24, 2013 - BIOLOGIX HAIR INC. | f8k012413ex99i_biologix.htm |
| EX-10.1 - 2013 STOCK OPTION PLAN - BIOLOGIX HAIR INC. | f8k012413ex10i_biologix.htm |
| EX-10.2 - FORM OF STOCK OPTION AGREEMENT - BIOLOGIX HAIR INC. | f8k012413ex10ii_biologix.htm |
| EX-99.3 - NEWS RELEASE DATED JANUARY 17, 2013 - BIOLOGIX HAIR INC. | f8k012413ex99iii_biologix.htm |
Exhibit 99.2
Biologix Hair Inc. Announces Opening of Corporate Communications
Center in Halifax, Appoints Janice Matthews as VP Corporate
Communications
Toronto, Ontario – January 22, 2013 – Biologix Hair Inc. (OTCBB: TGPO; OTCQB: TGPO), has announced the opening of its Corporate Communications center in Halifax, Nova Scotia to lead the development and dissemination of Biologix marketing and related materials. The center will also serve as an in-house frontline point of contact for general inquiries about the Company and the Biologix Hair Therapy SystemTM as well as corporate questions from investors and shareholders. Those with clinician licensing questions are encouraged to contact the Clinician Licensing department in Toronto directly.
The Corporate Communications center will be located in the heart of the city in the Purdy's Wharf office complex, a high tech center with modern conveniences with a reliable, stable communications infrastructure. The area has a surplus of high quality talent available at lower labor costs as compared to other areas and Biologix has contracted with an international employee development group to train local staff. As an added benefit, Halifax lies within the Atlantic time zone (an hour ahead of Eastern), which helps bridge the time difference between Europe and North America, allowing for more efficient communication across the regions.
Janice Matthews has been appointed Vice President of Corporate Communications and will head up the center. Janice brings nearly three decades of experience in communications with a wide variety of clients from around the world. Ms. Matthews said, "I am excited about working with such a talented, forward-looking group of people in this cutting-edge opportunity and intend to put my experience and skills to work immediately to contribute value to the Biologix team. The Communication Center's placement in beautiful Halifax is certainly an added bonus for me."
Ron Holland, Biologix Chairman and CEO, stated, "Janice has strong experience in creating clear marketing and related materials and brings a skill set that will be of real benefit to Biologix as we continue to expand. We are pleased to have her head up our Halifax Communications center."
About Biologix Hair Inc. and Biologix Hair Science Ltd.
Biologix Hair Inc. (Biologix Hair), together with its wholly owned biotechnology subsidiary, Biologix Hair Science Ltd. TM (BHS), is focused on realizing the full market potential for its patent-pending hair loss formula – Biologix Revive – and its demonstrated ability to prevent and reverse the effects of alopecia, which plagues hundreds of millions worldwide.
Between mid-2004 and mid-2012, more than 30,000 pre-clinical-trial treatments of Biologix Revive were administered to 5,000-plus patients in South America suffering with varying degrees of alopecia, as well as people seeking preventive treatment. The participating treatment clinicians subjectively observed and reported that virtually 100% of preventive care clients continued to retain their healthy hair and an estimated 80-85% of the males and 90-plus% of the females treated for hair regeneration experienced significant regrowth of their own natural hair. And among alopecia areata patients, virtually total hair regrowth was observed in 100% of the cases. To date, no negative side effects have been reported.
BHS is currently focused on obtaining FDA approval for its breakthrough hair loss prevention and regeneration therapy and has initiated a research and development program with one of the world's leading medical research universities, the Beijing Institute of Technology (BIT). The R&D program, expected to take approximately twelve months to complete, is an important final step before formal clinical trials and the FDA approval process begins.
Additionally, on May 11, 2012, Venable LLC, the Washington-based law firm overseeing the worldwide IP and regulatory approval processes on behalf of BHS, filed a Patent Cooperation Treaty (PCT) application on behalf of BHS for Biologix Revive in Geneva, Switzerland. The PCT is an international treaty, administered by the World Intellectual Property Organization (WIPO), to which 144 countries have as of now contracted, including Canada and the United States.
Biologix management is determined to be in a ready position to capitalize on the high-margin sales potential of the Biologix Hair Therapy SystemTM, if and when FDA and other major market approvals are forthcoming.
As BHS advances the regulatory approval process, Biologix Hair, together with wholly owned subsidiary companies operated by BHS, are rapidly developing a global distribution network of licensed clinicians and medical practitioners seeking to become Certified Biologix Hair TherapistsTM and secure exclusive territorial purchasing and treatment rights for the Biologix Hair Therapy SystemTM.
Biologix Hair has decided not to risk creating any potential regulatory conflicts by offering treatment outside the United States and other major high-product-margin markets until FDA approval has been granted. Therefore, the Biologix Hair Therapy SystemTM is not yet available other than to the 5,000+ patients who participated in the pre-clinical-trials conducted in South America.
To learn more about Clinician Licensing opportunities, Click Here or call toll free +1 855.737.0333 or +1 647.344.5900.
Contact info for Biologix Hair Inc.
Corporate Communications
Toll Free: +1 855.292.8585
Phone: +1 902.801.7920
Email: CorporateCommunications@BiologixHair.com
Web: www.BiologixHair.com
Disclaimer
This announcement is not an offer to sell any Biologix Hair Inc. ("Biologix") securities. Offers for any given security are made only through applicable offering circulars and related documents filed with the SEC pursuant to the Securities Act of 1933 or the Securities Exchange Act of 1934. Certain statements contained herein and subsequent oral statements made by and on behalf of Biologix may contain "forward-looking statements". Such forward-looking statements are identified by words such as "intends," "anticipates," "believes," "expects" and "hopes" and includes, without limitation, the development of treatment centers and approval from regulatory authorities. Forward-looking statements express our expectations or predictions of future events or results. They are not guarantees and are subject to many risks and uncertainties. There are a number of factors beyond our control that could cause actual events or results to be significantly different from those described in the forward-looking statements. Any or all of our forward- looking statements in this report or in any other public statements we make may turn out to be wrong. We undertake no obligation to publicly update or review any forward-‐looking statements, whether as a result of new information, future developments or otherwise. In Canada, Europe and the United States, the Biologix treatment is not approved for use by Health Canada, EMA or the FDA. The company makes no representations that it will receive Health Canada, EMA or FDA approvals.